ストックスクリーナーアプリを入手
15.99
0.63%
0.16
Adlai Nortye Ltd Adr (ANL) 最新ニュース
Adlai Nortye at Morgan Stanley global healthcare conference: RAS push By Investing.com - Investing.com South Africa
Adlai Nortye (NASDAQ: ANL) readies new offerings as holders plan a large ADS resale - Stock Titan
Jefferies initiates Adlai Nortye stock with buy rating on drug potential - Investing.com Australia
Adlai Nortye (NASDAQ: ANL) Initiates Global Phase I Trial for AN4035 with Phase Ia Data Expected in Late 2027 - Kalkine Media
Adlai Nortye Launches Global Phase I Trial of First-in-Class RAS-Targeting ADC AN4035 - TipRanks
Lucid Capital Markets initiates Adlai Nortye stock with buy rating By Investing.com - Investing.com Nigeria
Lucid Capital Markets initiates Adlai Nortye stock with buy rating - investing.com
Adlai Nortye doses first patient in AN4035 cancer trial By Investing.com - Investing.com Canada
Adlai Nortye doses first patient in AN4035 cancer trial - Investing.com
Analysts Offer Insights on Healthcare Companies: Sysmex (OtherSSMXF) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Adlai Nortye CFO Ye Xiaofeng Reports Sale of 11,667 ADS in Two Open-Market Transactions - Kalkine Media
Adlai Nortye Calls September Extraordinary Meeting to Authorize Major Share Issuance and Board Changes - TipRanks
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - Eastern Progress
Adlai Nortye Redomiciles to Singapore and Updates Nasdaq Identity - TipRanks
Adlai Nortye (Nasdaq: ANL) shifts to Singapore with super-voting shares - Stock Titan
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High? - Yahoo Finance
HC Wainwright Increases Earnings Estimates for Adlai Nortye - MarketBeat
Adlai Nortye (NASDAQ:ANL) Stock Price Up 6.2%Still a Buy? - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Adlai Nortye Boosts Cash Reserves and Advances RAS-Focused Oncology Pipeline in First Half of 2026 - TipRanks
Adlai Nortye (ANL) Earnings Date and Reports 2026 $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportMoney Flow Index - dars.gov.et
Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated - TipRanks
Adlai Nortye receives approval to begin trial in Australia - Investing.com
Adlai Nortye Wins Australian Clearance to Launch First-in-Class Pan-RAS(ON) ADC Trial - TipRanks
ADAR1 Capital Management LLC Makes New $816,000 Investment in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Affinity Asset Advisors LLC Takes Position in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Adlai Nortye Begins Weekly Dosing Arm in Global Phase 1 Trial of RAS Inhibitor AN9025 - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV) - The Globe and Mail
Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained - TipRanks
Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com
Adlai Nortye expands scientific advisory board with two oncologists By Investing.com - Investing.com Nigeria
Adlai Nortye expands scientific advisory board with two oncologists - Investing.com
Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR – SWB:N2U0 - TradingView
Price to sales forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Enterprise value to EBIT forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Adlai Nortye Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ANL) - TradingView
Enterprise value to revenue forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Cantor Fitzgerald initiates Adlai Nortye stock with overweight rating By Investing.com - Investing.com Nigeria
Cantor Fitzgerald initiates Adlai Nortye stock with overweight rating - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Context Therapeutics (CNTX) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY) - The Globe and Mail
ANL Stock Price, Quote & Chart | ADLAI NORTYE LTD-ADR (NASDAQ:ANL) - ChartMill
Adlai Nortye initiated with an Outperform at Oppenheimer - TipRanks
Oppenheimer initiates Adlai Nortye stock coverage with Outperform By Investing.com - Investing.com Nigeria
0.82%
0.45%
大文字化:
|
ボリューム (24 時間):